Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Revenue of Oncolytics Biotech Inc. (ONCY)
Revenue in 2023 (TTM): $
According to Oncolytics Biotech Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Oncolytics Biotech Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-403,000 | $-33,710,000 | $-27,655,000 | $-27,752,000 |
| 2022 | $ | $-392,000 | $-26,831,000 | $-24,751,000 | $-24,835,000 |
| 2021 | $ | $-452,065 | $-25,664,361 | $-26,254,852 | $-26,304,279 |
| 2020 | $ | $-446,187 | $-25,370,000 | $-22,505,057 | $-19,551,108 |
| 2019 | $ | $-485,574 | $-20,020,513 | $-33,122,888 | $-45,552,419 |
| 2018 | $ | $-95,375 | $-17,177,410 | $-16,489,183 | $-17,037,225 |
| 2017 | $ | $-90,768 | $-15,514,686 | $-15,475,353 | $-15,616,851 |
| 2016 | $ | $-162,233 | $-15,132,274 | $-15,130,605 | $-15,139,979 |
| 2015 | $ | $-180,411 | $-13,737,290 | $-13,719,842 | $-13,722,995 |
| 2014 | $ | $ | $-18,659,445 | $-18,612,556 | $-18,619,335 |
| 2013 | $ | $ | $-23,767,101 | $-23,527,239 | $-23,532,647 |
| 2012 | $4.85 M | $ | $-36,578,775 | $-36,343,047 | $-36,373,521 |
| 2011 | $ | $-5,334,582 | $-27,928,996 | $-29,004,701 | $-29,044,701 |
| 2010 | $ | $-4,190,403 | $-19,286,567 | $-19,966,161 | $-19,973,772 |
| 2009 | $ | $-3,782,507 | $-16,746,281 | $-16,972,705 | $-16,995,741 |
| 2008 | $ | $-4,311,575 | $-17,659,206 | $-17,550,204 | $-17,550,204 |
| 2007 | $ | $ | $-15,833,070 | $-15,642,191 | $-15,642,191 |
| 2006 | $ | $ | $-14,534,113 | $-14,297,524 | $-14,297,524 |
| 2005 | $783.46 K | $783.46 K | $-12,456,453 | $-12,783,356 | $-12,781,830 |
| 2004 | $699.76 K | $699.76 K | $-12,580,237 | $-12,956,120 | $-12,956,120 |
| 2003 | $313.31 K | $313.31 K | $-5,954,723 | $-8,510,479 | $-8,544,031 |
| 2002 | $208.87 K | $208.87 K | $-6,177,148 | $-6,751,385 | $-6,091,486 |
| 2001 | $ | $ | $-6,671,787 | $-6,482,031 | $-6,171,461 |
| 2000 | $310 K | $310 K | $-4,440,458 | $-3,739,964 | $-3,613,152 |
| 1999 | $1 | $1 | $-575,691 | $ | $-574,462 |